Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. - Wikidata - wikimedia - TriplyDB

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

http://www.wikidata.org/entity/Q34877463

about

Adjuvant systemic therapy in older women with breast cancer Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Optimal management of breast cancer in the elderly patient: current perspectives Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.Time-dependent endpoints as predictors of overall survival in multiple myeloma Status of adjuvant endocrine therapy for breast cancer.Adjuvant therapy for renal cell carcinoma: past, present, and future Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.Breast Cancer 2012 - New Aspects Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.Aromatase inhibitors and calcium absorption in early stage breast cancer.Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.The impact of Anastrazole and Letrozole on the metabolic profile in an experimental animal model.Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial.Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer.Assessing causal relationships between treatments and clinical outcomes: always read the fine print.Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.Inconsistent selection and definition of local and regional endpoints in breast cancer research.Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer.Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice.Update of the Phase III trial 'GRETA' of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women.Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial.Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.

P2860

Q26741523-07AF7A12-454F-4F03-B6A3-8C12A1DF00DE Q26782584-C72CB76A-B1D7-4254-B729-C0A0B7B4B987 Q27002430-1B6FF54B-7738-4A1B-9D08-86A92641A779 Q27690879-07E5D22D-EF0A-487F-933B-99842EFBEF2F Q30313653-A246FC96-498E-4029-AD8F-BBB6721516AE Q30538040-796DB68C-80BD-47CF-BF35-3FC9981CF17A Q33739138-F0D8A5D2-A8EC-4F22-80D6-B3946886929B Q34005127-DACCBD12-A6F2-4BA8-868A-CD7BB73F8448 Q34007066-E0EB1035-82D8-49CE-B198-E9E28114E1F0 Q34209663-9AB15C47-8B5D-42D7-A67D-9930728309FC Q34245992-BBBE5AA7-09F0-4CB0-A1C4-601EFC3CB453 Q35557992-9B1CB6C3-B085-47A4-B1C9-9EB7DEAF03F2 Q35607675-8D25FC18-23C9-4D6C-99FD-931037DEB985 Q35617340-42B955C0-FD8A-453F-BEFF-BAA86C737D1A Q35808358-804B40D0-9A9D-46B5-8A28-08FF0AAB186A Q35842986-32902568-873A-43AD-A346-B0F6C6E0EC36 Q35909220-5B9C7F66-3E64-4ED2-A230-FB9182273460 Q35998828-1F3C00F0-5D42-4E30-BE6B-A4013C0E6203 Q36037270-204AD35E-7C51-43AE-AB76-535300687340 Q36140045-43187504-1D08-4A37-9A85-CE52EF1A487F Q36229869-E48B3973-A6F8-43A1-8964-D31437CB60F9 Q36278395-2ED579E5-84BB-4FE2-A8F2-F1DF8A24E196 Q36333464-B3BE42B7-ACBF-4ED8-B3DB-EAE70EBA244A Q36368902-897894E9-E506-4B95-9F05-3B485EED3DB7 Q36514409-3E6C177F-4664-43FD-AA57-0A6DE797A2D3 Q36713321-5EA6DA78-4030-47BC-9BD4-D0F7FC0859D9 Q36895055-E790D888-F1BD-49E4-8629-9FA9F627F5F9 Q36946008-9E24A8C3-4BD4-4C6E-864E-798321E7A3FE Q37081944-4FB17264-302A-4D01-AFD7-3F84B48D0279 Q37130142-521760FB-326B-4144-9F19-4966EE8C2696 Q37575017-FBE1260E-CA39-4B41-9DB8-1FC629C22BD0 Q37882393-C09EE76F-E536-4A5B-89F7-00DBCF24B8FD Q37955223-333DDA71-929D-43E3-9F31-9146D9B5BCF8 Q38259456-1CA22D99-C0F5-4BE8-BA9F-606C67D6B99D Q38386693-CF5B0C59-1514-4DA5-A06D-8B47885831CC Q38749680-B1F8E437-3190-4FC5-BF38-8DAC3B478F59 Q39000113-D5579100-5555-4DA3-B21E-422579249E3D Q39100596-DC7C6FFC-B654-4750-A602-1B5690EE2978 Q40143985-7C33AA15-06E7-40C2-A0AA-7A9F5AEF07A0 Q43567721-77F4C0ED-76B3-4E6C-AEF2-2E878EE67CA4

P2860

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

http://www.wikidata.org/entity/Q34877463

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@ast

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@en

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@nl

type

label

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@ast

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@en

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@nl

prefLabel

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@ast

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@en

Analyses adjusting for selecti ...... moxifen in the BIG 1-98 study.

@nl

P1433

Q34877463-3D6212DF-C7F0-48ED-8AAD-B3406B5D5697

P1476

Q34877463-FADBABCE-7815-4035-82B4-B28283A1B6D7

P2093

Q34877463-05C3BD07-7E90-46B0-AC98-8817DB9CF06F

Q34877463-1126A791-CF2E-4D6A-B0AE-DDFBA335CBAE

Q34877463-12F7FBB0-9305-4D57-85CC-ADF9354727F5

Q34877463-2C9A3259-792A-4A74-A973-8F6784C1E9FB

Q34877463-55219F0F-208F-4ECE-907B-298C58543198

Q34877463-5F2E5844-6707-45E4-A88D-3A368A37C1C2

Q34877463-74CAC1AD-358B-4939-B3DD-93F1A126DA1A

Q34877463-76993266-D9E0-4ABA-8118-80C54675ED61

Q34877463-7D109BD4-09C0-4B0E-9B9B-07F350B68996

Q34877463-95435925-43C8-4B4C-95ED-E9A2DCE5886B

P2860

Q34877463-270152A5-3D7D-4F96-B113-5A2D8E222138

Q34877463-3122D025-E4D2-4BB0-B55F-1846E9F5A055

Q34877463-6122FAE3-0262-4CE0-9058-384DD5EAF6BB

Q34877463-613FCCD8-CCDD-4F01-910A-8995885E2ABF

Q34877463-6FAECE0F-906B-419F-A40C-50C1DD8BFC78

Q34877463-6FB9149B-0558-443D-A195-C4BFE5309098

Q34877463-716A8563-1A26-49C0-AFA4-F603FA2C80FB

Q34877463-75E3C81F-0081-4EED-8A98-0F4CAEA7C96A

Q34877463-8FDB2B69-47EE-44D7-9E9F-AF5D20C955E6

Q34877463-97785996-0086-42C9-87AB-4FDC30F1C5F5

P304

Q34877463-DD62B1BF-0D7C-4C8F-AF8F-67F2EB128F71

P31

Q34877463-ADE211C1-BC02-488C-8D96-7C1CA37208D8

P356

Q34877463-3FA74197-7956-4716-8F38-38E2D1CECF94

P407

Q34877463-53D18F28-5254-4795-9C00-B8248945E682

P433

Q34877463-A49A2BE4-21A7-4055-8FFA-6D0C774879A4

P478

Q34877463-7FE43689-4E47-455C-A274-110CDFEA705C

P50

Q34877463-AFB6254C-43E9-486A-895B-F98CCE210EE9

Q34877463-DF114205-1DA9-4931-8EC6-5DE825B98609

Q34877463-DF8A067F-D4D7-47BD-9262-860008421650

P577

Q34877463-44AE6578-1E18-4FC2-A5BA-499FAFF554D0

P698

Q34877463-1512381A-2893-4A5C-816A-AF0C61095653

P932

Q34877463-93CBF7B8-6AC5-40E3-8FC3-1A1266ECB76E

P356

JCO.2010.31.6455

P1433

Journal of Clinical Oncology

P1476

Analyses adjusting for selecti ...... amoxifen in the BIG 1-98 study

@en

P2093

Alan S Coates

http://www.w3.org/2001/XMLSchema#string

Anita Giobbie-Hurder

http://www.w3.org/2001/XMLSchema#string

Aron Goldhirsch

http://www.w3.org/2001/XMLSchema#string

Beat Thürlimann

http://www.w3.org/2001/XMLSchema#string

Henning Mouridsen

http://www.w3.org/2001/XMLSchema#string

Ian Smith

http://www.w3.org/2001/XMLSchema#string

István Láng

http://www.w3.org/2001/XMLSchema#string

Jacquie Chirgwin

http://www.w3.org/2001/XMLSchema#string

John F Forbes

http://www.w3.org/2001/XMLSchema#string

Karen N Price

http://www.w3.org/2001/XMLSchema#string

P2860

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Estrogen therapy and coronary-artery calcification.

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

P304

1117-1124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.31.6455

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Tadeusz Pieńkowski

Andrew M. Wardley

P577

2011-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21321298

http://www.w3.org/2001/XMLSchema#string

P932

3083867

http://www.w3.org/2001/XMLSchema#string